Physician profile
Vijay Joshi
NPI 1174522692
$7,712.27
in general payments reported to CMS, 2019-2025
47 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,664 · 2020: $149 · 2021: $462 · 2022: $800 · 2023: $1,360 · 2024: $1,480 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,624 · Education: $13.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,624.27 |
| Education | $13.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,031.66 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $822.67 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $736.22 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $520.01 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $501.41 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $476.00 | 2019-2025 | |
| Dexcom, INC. | $331.94 | 2020-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $294.64 | 2024-2025 | |
| Abbvie INC. | $280.66 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.89 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $204.00 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Amneal Pharmaceuticals LLC | $173.28 | 2021-2025 | Unithroid |
| Radius Health, INC. | $155.00 | 2023-2025 | Tymlos |
| Calliditas Therapeutics US INC. | $125.51 | 2023-2025 | Tarpeyo |
| Insulet Corporation | $114.51 | 2019-2024 | Omnipod |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $102.13 | 2024-2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $100.59 | 2023-2024 | |
| Ibsa Pharma INC. | $99.19 | 2019-2023 | Tirosint, Licart |
| Tandem Diabetes Care, INC. | $96.01 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ge Healthcare | $95.67 | 2023 | |
| Medtronic, INC. | $93.22 | 2021-2025 | Minimed 780g |
| Kyowa Kirin, INC. | $91.15 | 2023-2025 | Crysvita |
| Merck Sharp & Dohme LLC | $76.45 | 2019-2020 | |
| Corcept Therapeutics | $64.23 | 2019-2025 | Korlym |
| Horizon Therapeutics Plc | $62.63 | 2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $57.85 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Madrigal Pharmaceuticals | $53.31 | 2025 | Rezdiffra |
| Halozyme INC | $52.10 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $51.18 | 2024-2025 | Baqsimi |
| Mallinckrodt Hospital Products INC. | $50.93 | 2024-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $49.79 | 2025 | Orencia |
| Travere Therapeutics, INC. | $48.86 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $43.35 | 2025 | Opsynvi, Uptravi, Opsumit |
| Ucb, INC. | $41.58 | 2025 | Bimzelx |
| Genentech USA, INC. | $38.33 | 2024 | Actemra |
| Janssen Pharmaceuticals, INC | $35.55 | 2019-2020 | |
| Cequr Corporation | $35.11 | 2024 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $35.11 | 2025 | |
| Embecta Corp. | $30.93 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ultragenyx Pharmaceutical INC. | $27.19 | 2023 | |
| Almatica Pharma LLC | $26.93 | 2025 | Teriparatide |
| Sobi, INC | $26.58 | 2025 | |
| Recordati_rare_diseases_inc. | $26.34 | 2025 | Isturisa |
| Ani Pharmaceuticals, INC. | $24.54 | 2025 | Purified Cortrophin Gel |
| Alvogen INC | $24.34 | 2025 | Teriparatide |
| Becton, Dickinson and Company | $16.21 | 2019 | |
| Lifescan, INC. | $15.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Joshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.